Canada's Canopy Growth Q1 revenue slightly misses estimates
CGC•Outlook
- Company anticipates further financial improvements, especially in H2 FY2027, as MTL Cannabis integration completes
- Canopy Growth expects growth in each end market driven by clear strategies and increased high-quality flower supply
- Company sees expanded revenue opportunities and meaningful synergies from MTL Cannabis acquisition
Overview
- Canada cannabis producer's fiscal Q1 net revenue rose 13% yr/yr, slightly missed analyst expectations
- Adjusted EBITDA loss for fiscal Q1 narrowed by 59% yr/yr, driven by revenue growth and cost savings
- Adjusted gross margin improved to 31% from 25% yr/yr
Result Drivers
- MTL Cannabis acquisition - Co said acquisition led to increased supply of high-quality flower and expanded revenue opportunities, supporting growth in Canada medical and adult-use cannabis
- Segment sales growth - Co reported net revenue growth in Canada medical cannabis (22%), Canada adult-use cannabis (10%), international markets cannabis (10%), and Storz & Bickel (6%)
- Cost rationalization - Storz & Bickel gross margin rose due to cost rationalization and recovery of certain U.S. tariffs
